

# Memorandum



Subject Initial 2010 Procurement Quota Letter as of 12/07/09 (DFN:	Date  <b>DEC 15 2009</b>
--	--------------------------------

To  
Christine A. Sannerud, Ph.D., Chief  
Drug & Chemical Evaluation Section  
Office of Diversion Control

From  
*Barbara J. Boeckholdt*  
Barbara J. Boeckholdt, Chief  
Regulatory Section  
Office of Diversion Control

On December 07, 2009, this section received your e-mail requesting a review of one hundred and ninety seven (197) quota applications to determine if there are any pending administrative/legal actions against these applicants and to advise ODE of the findings.

ODGR conducted reviews (NADDIS, CSA, etc) as well as surveyed the responsible field offices for their input and advisement. Provided below are the results and recommendations.

There was no derogatory information found, with the exception of the following:

(b)(4);(b)(7)(E)

Currently under review/investigation

Currently under review/investigation

Retired

Per New York, this location is closing in 1/2010 and/or 2/2010 no quota is needed

OTSC placed against registration 10/30/08  
Settlement discussions are ongoing.

Currently under review/investigation

Currently under review/investigation

Currently under review/investigation

Currently under review/investigation

(b)(4);(b)(7)(E)

Retired

Per consultation with the field office, DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the one hundred and ninety seven (197) quota applications.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC:

(b)(6);(b)(7)(C)

Attachments:


Email Request and Responses

# Memorandum



Subject Controlled Substance Quota Requests for 2010 Initial Quotas for 12/22/2009 (DFN:630-08.2)	Date December, 24, 2009
--	----------------------------

To  
Christine A. Sannerud, Ph.D., Chief  
Drug & Chemical Evaluation Section  
Office of Diversion Control

From   
Barbara J. Boockholdt, Chief  
Regulatory Section  
Office of Diversion Control

On December 22, 2009, this section received your e-mail requesting a review of seven (7) quota applications, to determine if there is any pending administrative/legal action against these applicants and to advise ODE of the findings.



ODGR conducted reviews (NADDIS, CSA, etc) as well as surveyed the responsible field offices for their input and advisement. Provided below are the results and recommendations.

There was no derogatory information found on any of the applicants.

Abbott Pharmaceuticals PR LTD  
Med Shop Total Care Pharmacy  
Novartis Pharmaceutical Corp  
Research Triangle Institute  
Sigma Aldrich Research  
Tedor Pharma  
Tris Pharma Inc

(b)(4);(b)(7)(E)

Per consultation with the field offices, DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the above stated quota applications.

If you have any questions pertaining to this information, please feel free to contact me  or SC 

Attachments:  
Email Request

(b)(6);(b)(7)(C)

**From:** (b)(6);(b)(7)(C)  
**Sent:** Tuesday, December 22, 2009 2:00 PM  
**To:** Boockholdt, Barbara J.; (b)(6);(b)(7)(C)  
**Cc:** (b)(6);(b)(7)(C); (b)(6);(b)(7)(C); Bannerud, Christine A  
**Subject:** additional initial 2010 quota applications received as of 12/22/09

Good afternoon Barbara,

Below is a list of quota applications from DEA-registered manufacturers received as of December 22, 2009.

We request that ODG review for pending administrative/legal action against these applicants and advise ODE of your findings.

Thanks in advance!

Company Name	Registration #
Abbott Laboratories North Chicago Med Shop Total Care Pharmacy Novartis Pharmaceutical Corporation Research Triangle Research 1 Sigma-Aldrich Research Biochemicals Tedor Pharma Inc. Tris Pharma, Inc.	(b)(4);(b)(7)(E)

Drug Science Specialist  
ODEQ

Phone: (b)(6);(b)(7)(C)  
Fax: (b)(6);(b)(7)(C)  
e-mail: (b)(6);(b)(7)(C)@USDOL.gov


DEA Headquarters  
Attn: Drug & Chemical Evaluation Section/ODE  
8701 Morrisette Drive  
Springfield, Virginia 22152



# Memorandum

Subject Quota Requests as of January 6, 2010 (DFN: 630-08.2)	Date  <p style="text-align: center;">JAN 16 2010</p>
--	--

To  
 Christine A. Sannerud, Ph.D., Chief  
 Drug & Chemical Evaluation Section  
 Office of Diversion Control

From   
 Barbara J. Boockholdt, Chief  
 Regulatory Section  
 Office of Diversion Control

On January 7, 2010, this section received your e-mail requesting a review of thirty-three (33) quota applications from twenty-eight (28) registered manufacturers to determine if there are any pending administrative/legal actions against these applicants and to advise ODE of the findings.

ODGR conducted reviews (NADDIS, CSA, etc), as well as surveyed the responsible field offices for their input and recommendations. Provided below are the results and recommendations.

**QUOTA APPLICANTS WITH NO ADVERSE OR DEROGATORY INFORMATION**

- Denison Pharmaceuticals (9517)
- RIJ Pharmaceutical (9518)
- Aputit (9519)
- Anderson Packaging, Inc. (9520)
- Fisher (9521)
- Cody Laboratories (9522)
- Boehringer Ingelhelm (9524)
- Noramco Georgia (9525)
- Noramco Delaware (9526)
- Archimica (9527)
- Lehigh Valley Technologies, Inc. (9528)
- Rhodes (9529)
- AMRI (9530)
- Cedarburg (9531)
- Chattem (9532)
- Chattem (9533)
- Sigma Aldrich (9534)
- Noramco Georgia (9535)
- Mallinckrodt St. Louis (9536)
- Norac (9537)

(b)(4);(b)(7)(E)

PalliRx, Inc. (9538)  
 Contract Pharmacal Corp (9540)  
 ANIP (9541)  
 ANIP (9542)  
 ANIP (9543)  
 National Center (9544) (1 of 2)  
 Upsher-Smith (9545)  
 Rhodes (9546)  
 Catalent (9547)  
 Cerilliant (9548)  
 Pharmedium (9549) (1 of 2)

(b)(4);(b)(7)(E)

**QUOTA APPLICANTS WITH ADVERSE OR DEROGATORY INFORMATION**

(b)(4);(b)(7)(E)

Currently Under Review/Investigation

Expired – Currently authorized to conduct business as usual with the expired license until a decision is reached on the registration

Per consultation with the field office, DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the quota applications.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC

(b)(6);(b)(7)(C)

# Memorandum



Subject Additional Quota Requests as of January 11, 2010 (DFN: 630-08.2)	Date  JAN 16 2010
--	-------------------------

To  
Christine A. Sannerud, Ph.D., Chief  
Drug & Chemical Evaluation Section  
Office of Diversion Control

From *[Signature]*  
Barbara J. Boockholdt, Chief  
Regulatory Section  
Office of Diversion Control

On January 11, 2010, this section received your e-mail requesting a review of eleven (11) quota applications from nine (9) registered manufacturers to determine if there are any pending administrative/legal actions against these applicants and to advise ODE of the findings.

ODGR conducted reviews (NADDIS, CSA, etc), as well as surveyed the responsible field offices for their input and recommendations. Provided below are the results and recommendations.

### QUOTA APPLICANTS WITH NO ADVERSE OR DEROGATORY INFORMATION

- Elite (9550)
- Dispensing Solutions, Inc. (9551)
- Palmetto State Pharmaceuticals (9552)
- Mallinckrodt Webster Groves (9553)
- Amerisource (9554)
- Mallinckrodt St. Louis (9555)
- Azopharma (9556)
- Sharp (9557)
- Sharp (9558)
- Sharp (9559)
- Norwich (9560)

(b)(4);(b)(7)(E)

Per consultation with the field offices, DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the quota applications.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC


(b)(6);(b)(7)(C)

# Memorandum



Subject Quota Requests as of January 6, 2010 (DFN: 630-08.2)	Date  JAN 16 2010
--	-------------------------

To  
Christine A. Sannerud, Ph.D., Chief  
Drug & Chemical Evaluation Section  
Office of Diversion Control

From   
Barbara J. Boockholdt, Chief  
Regulatory Section  
Office of Diversion Control


On January 7, 2010, this section received your e-mail requesting a review of thirty-three (33) quota applications from twenty-eight (28) registered manufacturers to determine if there are any pending administrative/legal actions against these applicants and to advise ODE of the findings.

ODGR conducted reviews (NADDIS, CSA, etc), as well as surveyed the responsible field offices for their input and recommendations. Provided below are the results and recommendations.

## QUOTA APPLICANTS WITH NO ADVERSE OR DEROGATORY INFORMATION

- Denison Pharmaceuticals (9517)
- RIJ Pharmaceutical (9518)
- Aputit (9519)
- Anderson Packaging, Inc. (9520)
- Fisher (9521)
- Cody Laboratories (9522)
- Boehringer Ingelhelm (9524)
- Noramco Georgia (9525)
- Noramco Delaware (9526)
- Archimica (9527)
- Lehigh Valley Technologies, Inc. (9528)
- Rhodes (9529)
- AMRI (9530)
- Cedarburg (9531)
- Chattem (9532)
- Chattem (9533)
- Sigma Aldrich (9534)
- Noramco Georgia (9535)
- Mallinckrodt St. Louis (9536)
- Norac (9537)

(b)(4);(b)(7)(E)





PalliRx, Inc. (9538)  
 Contract Pharmacal Corp (9540)  
 ANIP (9541)  
 ANIP (9542)  
 ANIP (9543)  
 National Center (9544) (1 of 2)  
 Upsher-Smith (9545)  
 Rhodes (9546)  
 Catalent (9547)  
 Cerilliant (9548)  
 Pharmedium (9549) (1 of 2)

(b)(4);(b)(7)(E)

**QUOTA APPLICANTS WITH ADVERSE OR DEROGATORY INFORMATION**

(b)(4);(b)(7)(E)

Currently Under Review/Investigation

Expired - Currently authorized to conduct business as usual with the expired license until a decision is reached on the registration

Per consultation with the field office, DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the quota applications.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC

(b)(6);(b)(7)(C)

(b)(6);(b)(7)(C)

# Memorandum



Subject

Additional Quota Requests as of January 14, 2010  
(DFN: 630-08.2)

Date

JAN 20 2010

To

Christine A. Sannerud, Ph.D., Chief  
Drug & Chemical Evaluation Section  
Office of Diversion Control

From

*[Signature]*  
Barbara J. Boockholdt, Chief  
Regulatory Section  
Office of Diversion Control

On January 14, 2010, this section received your e-mail requesting a review of eighteen (18) quota applications from eleven (11) registered manufacturers to determine if there are any pending administrative/legal actions against these applicants and to advise ODE of the findings.

ODGR conducted reviews (NADDIS, CSA, etc), as well as surveyed the responsible field offices for their input and recommendations. Provided below are the results and recommendations.

## QUOTA APPLICANTS WITH NO ADVERSE OR DEROGATORY INFORMATION

Alza (9562)  
Sovereign (9563)  
Glatt Air (9564)  
Glatt Air (9565)  
Cambrex (9566)  
Siemens Healthcare Diagnostics Inc. (9569)  
AAIPharma (9570)  
AAIPharma (9571)  
AAIPharma (9572)  
Norwich (9573)  
Norwich (9574)  
Norwich (9575)  
AAIPharma (9576)  
Novartis Consumer Health Lincoln (9577)  
Hisamitsu (9578)  
Fisher (9579)  
United Liquid (9580)  
Fisher (9591)

(b)(4);(b)(7)(E)

Per consultation with the field offices, DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the quota applications.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC (b)(6);(b)(7)(C)



# Memorandum

<p>Subject</p> <p>Additional Quota Applications Received through January 20, 2010 (DFN: 630-08.2)</p>	<p>Date</p> <p>JAN 22 2010</p>
---	--------------------------------

To: Christine A. Sannerud, Ph.D., Chief  
Drug & Chemical Evaluation Section  
Office of Diversion Control

From: *[Signature]*  
Barbara J. Boockholdt, Chief  
Regulatory Section  
Office of Diversion Control

On January 20, 2010, this section received your e-mail requesting a review of twenty-two (22) quota applications from twenty-one (21) registered manufacturers to determine if there are any pending administrative/legal actions against these applicants and to advise ODE of the findings.

ODGR conducted reviews (NADDIS, CSA, etc), as well as surveyed the responsible field offices for their input and recommendations. Provided below are the results and recommendations.

**QUOTA APPLICANTS WITH NO ADVERSE OR DEROGATORY INFORMATION**

- Cerilliant (9597)
- Cambrex (9598)
- Noramco (9599)
- Ohm Laboratories (9600)
- Mallinckrodt St. Louis (9601)
- Norac (9602)
- Bayer (9603)
- AAIPharma (9604)
- Boehringer Ingelheim (9605) (1 of 2)
- Actavis (9606)
- Purdue (9607)
- Johnson Matthey (9608)
- Mikart (9609)
- Quality Assurance (9612)
- Sharp Corporation (9613)
- DSM (9614)
- Anderson Packaging, Inc. (9615)
- Anderson Packaging, Inc. (9616)
- Epic Pharma (9617)
- Impax Laboratories, Inc. (9618)(1 of 2)
- Impax Laboratories, Inv. (9618)(2 of 2)

(b)(4);(b)(7)(E)

ODGR is waiting for further clarification/response from the responsible field office for the below stated manufacture. Updated information will be provided upon receipt.

(b)(4);(b)(7)(E)

Per consultation with the field offices, DIA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the quota applications.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC


(b)(6);(b)(7)(C)

# Memorandum



Subject  Additional Quota Applications Received through January 20, 2010 (DFN: 630-08.2)	Date  MAR 17 2010
---	-------------------------

To  
  
Christine A. Sannerud, Ph.D., Chief  
Drug & Chemical Evaluation Section  
Office of Diversion Control

From   
Barbara J. Boockholdt, Chief  
Regulatory Section  
Office of Diversion Control

Reference is made to a memorandum submitted to your office on January 22, 2010 regarding the above stated subject matter. This memorandum serves to update the response from the responsible field office. This section submitted one (1) registrant whose quota request information was pending field review.



This office conducted a review (NADDIS, CSA, etc.) as well as surveyed the responsible field office for their input and advisement. Provided below are the result and recommendation:

**QUOTA APPLICANT WITH NO ADVERSE OR DEROGATORY INFORMATION**

Boehringer Ingelheim Vetmedica, Inc.

(b)(4);(b)(7)(E)

ODG recommends approval of Boehringer's quota request.

If you have any questions pertaining to this information, please feel free to contact me  or SC 



**Memorandum**

Subject

Additional Quota Requests as of January 25, 2010  
(DFN: 630-08.2)

Date

JAN 27 2010

To

Christine A. Samnerud, Ph.D., Chief  
Drug & Chemical Evaluation Section  
Office of Diversion Control

From

Barbara J. Boeckholdt, Chief  
Regulatory Section  
Office of Diversion Control

On January 25, 2010, this section received your e-mail requesting a review of fourteen (14) quota applications from eleven (11) registered manufacturers to determine if there are any pending administrative/legal actions against these applicants and to advise ODE of the findings.

ODGR conducted reviews (NADDIS, CSA, etc.) as well as surveyed the responsible field offices for their input and recommendations. Provided below are the results and recommendations.

**QUOTA APPLICANTS WITH NO ADVERSE OR DEROGATORY INFORMATION**

- Sharp Corporation (9619)
- Elsobyl Laboratories (9621)
- Noramco (9625)
- Micron Technologies, Inc. (9626)
- Safecor (9627)
- Austin Pharma (9628)
- Sigma-Aldrich (9629)
- Eminent (9634)
- Siegfried (9635)
- Siegfried (9636)
- Siegfried (9637)
- Watson (9638)
- Watson (9639)
- AAIPharma (9640)

(b)(4);(b)(7)(E)

Per consultation with the field offices, DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the quota applications.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC

(b)(6);(b)(7)(C)

(b)(6);(b)(7)(C)

# Memorandum



Subject

Additional Quota Requests as of January 28, 2010  
(DFN: 630-08.2)

Date

FEB 05 2010

To

Christine A. Sannerud, Ph.D., Chief  
Drug & Chemical Evaluation Section  
Office of Diversion Control

From

*for Barbara J. Boockholdt*  
Barbara J. Boockholdt, Chief  
Regulatory Section  
Office of Diversion Control

On January 28, 2010, this section received your e-mail requesting a review of nine (09) quota applications from eight (08) registered manufacturers to determine if there are any pending administrative/legal actions against these applicants and to advise ODE of the findings.

ODGR conducted reviews (NADDIS, CSA, etc), as well as surveyed the responsible field offices for their input and recommendations. Provided below are the results and recommendations.

## QUOTA APPLICANTS WITH NO ADVERSE OR DEROGATORY INFORMATION

Pharmacia & Upjohn (9646)  
Sharp Corporation (9647)  
Pharmaceutical Manufacturing Research Services (9648)  
Catalent (9649)  
Pharmaceutics International (9650)  
Deltex (9655)  
Consolidated (9656)  
Ameridose, LLC (9658)  
Ameridose, LLC (9659)

(b)(4);(b)(7)(E)

Per consultation with the field offices, DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the quota applications.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC

(b)(6);(b)(7)(C)



# Memorandum




Subject Additional Quota Letters Received as of February 1, 2010 (DFN: 630-08.2)	Date  FEB 02 2010
--	-------------------------

To

Christine A. Sannerud, Ph.D., Chief  
Drug & Chemical Evaluation Section  
Office of Diversion Control

From

  
Barbara J. Boockholdt, Chief  
Regulatory Section  
Office of Diversion Control

On February 1, 2010, this section received your e-mail requesting a review of thirteen (13) quota applications from seven (07) registered manufacturers to determine if there are any pending administrative/legal actions against these applicants and to advise ODE of the findings.

ODGR conducted reviews (NADDIS, CSA, etc), as well as surveyed the responsible field offices for their input and recommendations. Provided below are the results and recommendations.

### QUOTA APPLICANTS WITH NO ADVERSE OR DEROGATORY INFORMATION

Unit Dose Solutions (9663)  
Unit Dose Solutions (9664)  
Unit Dose Solutions (9665)  
Unit Dose Solutions (9666)  
Unit Dose Solutions (9667)  
Unit Dose Solutions (9668)  
Unit Dose Solutions (9669)  
Novartis (9676)  
Mylan (9679 )  
Deltex (9671)  
Chattem (9674)  
Anderson Packaging, Inc. (9675)  
Alaunus Pharmaceutical (9678)

(b)(4);(b)(7)(E)

Per consultation with the field offices, DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the quota applications.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC

(b)(6);(b)(7)(C)

# Memorandum



Subject

Additional Quota Requests as of February 4, 2010  
(DFN: 630-08.2)


Date

FEB 04 2010

To

Christine A. Sannerud, Ph.D., Chief  
Drug & Chemical Evaluation Section  
Office of Diversion Control

From

  
Barbara J. Boockholdt, Chief  
Regulatory Section  
Office of Diversion Control

On February 4, 2010, this section received your e-mail requesting a review of ten (10) quota applications from registered manufacturers to determine if there are any pending administrative/legal actions against these applicants and to advise ODE of the findings.


ODGR conducted reviews (NADDIS, CSA, etc), as well as surveyed the responsible field offices for their input and recommendations. Provided below are the results and recommendations.


## QUOTA APPLICANTS WITH NO ADVERSE OR DEROGATORY INFORMATION

Actavis (9677)  
GE Healthcare (9680)  
AAIPharma (9681)  
Baxter (9682)  
Dispensing Solutions, Inc. (9683)  
Impax (9684)  
Sun Pharmaceuticals (9685)  
Rhodes (9686)  
Sigma-Aldrich (9687)  
Halo (9688)

(b)(4);(b)(7)(E)

Per consultation with the field offices, DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the quota applications.

If you have any questions pertaining to this information, please feel free to contact me  or SC



# Memorandum



Subject

Additional Quota Letters Received as of February 18, 2010  
(DFN: 630-08.2)


Date

FEB 19 2010

To

Christine A. Sannerud, Ph.D., Chief  
Drug & Chemical Evaluation Section  
Office of Diversion Control

From

  
Barbara J. Boockholdt, Chief  
Regulatory Section  
Office of Diversion Control

On February 18, 2010, this section received your e-mail requesting a review of thirty-seven (37) quota applications from twenty-two (22) registered manufacturers to determine if there are any pending administrative/legal actions against these applicants and to advise ODE of the findings.

ODGR conducted reviews (NADDIS, CSA, etc), as well as surveyed the responsible field offices for their input and recommendations. Provided below are the results and recommendations.

## QUOTA APPLICANTS WITH NO ADVERSE OR DEROGATORY INFORMATION

Stepan (9692)  
Purdue (9693)  
St. Mary's Medical Park Pharmacy (9695)  
Glatt Air (9696)  
Aputit (9699)  
Mylan (9700)  
Eminent (9702)  
Siegfried (9703)  
Mallinckrodt St. Louis (9705)  
Mallinckrodt St. Louis (9706)  
Fisher (9708)  
Fisher (9709)  
Nektar (9710)  
Nektar (9711)  
Noven (9712)  
Noven (9713)  
Noven (9714)  
Noven (9715)  
Noven (9716)  
Noven (9717)

(b)(4);(b)(7)(E)

Noven (9718)  
 Cantrell Drug Company (9719)  
 Pfizer (9720)  
 Amneal (9721)  
 Fisher (9722)  
 Cody Laboratories (9724)  
 Coating Place Inc. (9725)  
 DSM (9726)  
 Cody Laboratories (9728)  
 Mallinckdrodt (9729)  
 Fisher (9528) 9730  
 Gorbec Pharmaceutical Sves (9733)  
 DPT (9734)  
 Amneal (9735)  
 Purdue (9737)  
 Glatt Air (9738)  
 Purdue (9739)

(b)(4);(b)(7)(E)

Per consultation with the field office, DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the quota applications.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC

(b)(6);(b)(7)(C)

# Memorandum

5/3/3/10



Subject Additional Quota Letters Received as of February 25, 2010 (DFN: 630-08.2)	Date  <b>MAR 03 2010</b>
---	--------------------------------

To  
Christine A. Sannerud, Ph.D., Chief  
Drug & Chemical Evaluation Section  
Office of Diversion Control

From  
*Barbara J. Boockholdt*  
Barbara J. Boockholdt, Chief  
Regulatory Section  
Office of Diversion Control

On February 25, 2010, this section received your e-mail requesting a review of thirty-five (35) quota applications from twenty-six (26) registered manufacturers to determine if there are any pending administrative/legal actions against these applicants and to advise ODE of the findings.

ODGR conducted reviews (NADDIS, CSA, etc), as well as surveyed the responsible field offices for their input and recommendations. Provided below are the results and recommendations.

### QUOTA APPLICANTS WITH NO ADVERSE OR DEROGATORY INFORMATION

- Mylan (9741)
- Amneal (9743)
- Med Pharmex (9744)
- AAIPharma (9745)
- Par Pharmaceuticals (9746)
- Physicians Total Care (9747)
- Classic Pharmaceuticals (9748)
- Coating Place Inc. (9752)
- Mallinckrodt St. Louis (9753)
- St. Mary's (9754)
- St. Mary's (9755)
- St. Mary's (9756)
- St. Mary's (9757)
- St. Mary's (9758)
- St. Mary's (9759)
- Metrics (9761)
- Metrics (9763)
- Restek (9764)
- Mikart (9765) (1of2)
- Mikart (9765) (2of2)

(b)(4);(b)(7)(E)

Mallinckrodt St. Louis (9766)  
Nucare (9769)  
Aurolife (9770)  
Sharp Corporation (9771)  
Mylan (9772) (1 of 2)  
Mylan (9772) (2 of 2)  
Johnson Matthey (9773)  
King Pharmaceuticals (9775)  
Watson (9776)  
Lannett (9777) (1 of 2)  
Lannett (9777) (2 of 2)  
St. Mary's (9778)  
Neos Therapeutics, L.P (formerly Pharmafab) (9781)  
AAIPharma (9782)  
Rhodes (9784)

(b)(4);(b)(7)(E)

Per consultation with the field office, DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the quota applications.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC:

(b)(6);(b)(7)(C)

# Memorandum

5/31/10



Subject Additional Quota Requests as of March 1, 2010 (DFN: 630-08.2)	Date  <b>MAR 03 2010</b>
---	--------------------------------

To  
Christine A. Sannerud, Ph.D., Chief  
Drug & Chemical Evaluation Section  
Office of Diversion Control

From  
*Barbara J. Boeckholdt*  
Barbara J. Boeckholdt, Chief  
Regulatory Section  
Office of Diversion Control

On March 2, 2010, this section received your e-mail requesting a review of eight (08) quota applications from six (06) registered manufacturers to determine if there are any pending administrative/legal actions against these applicants and to advise ODE of the findings.

ODGR conducted reviews (NADDIS, CSA, etc), as well as surveyed the responsible field offices for their input and recommendations. Provided below are the results and recommendations.

### QUOTA APPLICANTS WITH NO ADVERSE OR DEROGATORY INFORMATION

- Barr Laboratories (9786)
- Acura Pharmaceutical Technologies (9787)
- Dispensing Solutions, Inc. (9788)
- Nexgen Pharma, Inc. (9790)
- Coating Place, Inc. (9791)
- Aptuit (9792)
- Aptuit (9793)
- Aptuit (9794)

(b)(4);(b)(7)(E)

Per consultation with the field offices, DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the quota applications.

If you have any questions pertaining to this information, please feel free to contact me

(b)(6);(b)(7)(C)


(b)(6);(b)(7)(C) or SC

# Memorandum



Subject Additional Quota Requests as of March 8, 2010 (DFN: 630-08.2)	Date  MAR 11 2010
---	-------------------------

To  
Christine A. Sannerud, Ph.D., Chief  
Drug & Chemical Evaluation Section  
Office of Diversion Control

From   
Barbara J. Boockholdt, Chief  
Regulatory Section  
Office of Diversion Control


On March 8, 2010, this section received your e-mail requesting a review of eighteen (18) quota applications from sixteen (16) registered manufacturers to determine if there are any pending administrative/legal actions against these applicants and to advise ODE of the findings.

ODGR conducted reviews (NADDIS, CSA, etc), as well as surveyed the responsible field offices for their input and recommendations. Provided below are the results and recommendations.

## QUOTA APPLICANTS WITH NO ADVERSE OR DEROGATORY INFORMATION

- Penick (9801)
- National Center (9802)
- Norameco Delaware (9803)
- Dispensing Solutions, Inc. (9804)
- Banyan (9805)
- Supelco (9807)
- Vintage Generics Bidco (9808)
- Vintage (9809)
- Spectrum (9811)
- Pharmaceutics International (9814)
- Pharmaceutics International (9815)
- Boehringer Ingelheim (9818)
- TG United Liquid (9819)
- Barr (9821)
- Sigma-Aldrich (9822)
- Mallinckrodt St. Louis (9825)
- Norameco Delaware (9826)
- Fisher (9828)

(b)(4);(b)(7)(E)





Per consultation with the field offices, DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the quota applications.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC

(b)(6);(b)(7)(C)

# Memorandum



Subject

Additional Quota Letter Received as of March 15, 2010  
(DFN: 630-08.2)


Date

MAR 16 2010

To

Christine A. Sannerud, Ph.D., Chief  
Drug & Chemical Evaluation Section  
Office of Diversion Control

From

  
Barbara J. Boockholdt, Chief  
Regulatory Section  
Office of Diversion Control

On March 15, 2010, this section received your e-mail requesting a review of twenty-seven (27) quota applications from twenty-four (24) registered manufacturers to determine if there are any pending administrative/legal actions against these applicants and to advise ODE of the findings.

ODGR conducted reviews (NADDIS, CSA, etc), as well as surveyed the responsible field offices for their input and recommendations. Provided below are the results and recommendations.

## QUOTA APPLICANTS WITH NO ADVERSE OR DEROGATORY INFORMATION

Siegfried (9704)  
Noramco Delaware (9831)  
Noramco Delaware (9832)  
Noramco Georgia (9833)  
Shire (9834)  
Activis (9836)  
Norwich (9837)  
Neos Therapeutics, LP (9839)  
Neos Therapeutics, LP (9840)  
Neos Therapeutics, LP (9841)  
Gallipot (9842)  
Hisamitsu California Laboratories (9843)  
Chattem (9844)  
DSM (9845)  
Cerilliant (9847)  
Mylan (9848)  
Hi-tech (9849)  
Fisher (9850)  
TEVA (9853)  
Epic (9854)

(b)(4);(b)(7)(E)

Cody (9855)  
Akorn (9857)  
Varian (9860)  
Mallinckrodt (9861)  
National Center for Natural Products Research (9862)  
Professional Compounding (9863)  
Banner (9864)

(b)(4);(b)(7)(E)

Per consultation with the field office, DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the quota applications.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC (b)(6);(b)(7)(C)

# Memorandum



Subject

Additional Quota Letters Received as of March 22, 2010  
(DFN: 630-08.2)


Date

MAR 24 2010

To

Christine A. Sannerud, Ph.D., Chief  
Drug & Chemical Evaluation Section  
Office of Diversion Control

From

  
Barbara J. Boockholdt, Chief  
Regulatory Section  
Office of Diversion Control


On March 22, 2010, this section received your e-mail requesting a review of twenty-three (23) quota applications from twenty (20) registered manufacturers to determine if there are any pending administrative/legal actions against these applicants and to advise ODE of the findings.

ODGR conducted reviews (NADDIS, CSA, etc), as well as surveyed the responsible field offices for their input and recommendations. Provided below are the results and recommendations.

## QUOTA APPLICANTS WITH NO ADVERSE OR DEROGATORY INFORMATION

Pharmaceutics International (9871)  
Watson (9872)  
Med Shop Total Care (9873)  
Fisher (9875)  
Shire (9876)  
Barr (9877)  
Barr (9878)  
DSM (9879)  
Paddock (9880)  
Actavis (9606)  
Barr (9882)  
Barr (9883)  
Barr (9884)  
Glatt Air (9885)  
Microgenics (9886)  
Almaet (9887)  
VistaPharm (9888)  
Epic (9889)  
Acura (9890)  
Nexgen Pharma Inc. (9891)

(b)(4);(b)(7)(E)



Ameridose, LLC (9892)(1 of 2)  
Ameridose, LLC (9892)(2 of 2)  
Central Admixture (9893)  
Schwarz Pharma (9894)

(b)(4);(b)(7)(E)

Per consultation with the field offices, DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the quota applications.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC


(b)(6);(b)(7)(C)

(b)(6);(b)(7)(C)

# Memorandum



Subject Additional Quota Letters Received as of March 29, 2010 (DFN: 630-08.2)	Date  MAR 30 2010
--	-------------------------

To  Christine A. Sannerud, Ph.D., Chief Drug & Chemical Evaluation Section Office of Diversion Control	From  Barbara J. Boockholdt, Chief Regulatory Section Office of Diversion Control
--	--

On March 29, 2010, this section received your e-mail requesting a review of twenty-four (24) quota applications from twenty-two (22) registered manufacturers to determine if there are any pending administrative/legal actions against these applicants and to advise ODE of the findings.

ODGR conducted reviews (NADDIS, CSA, etc), as well as surveyed the responsible field offices for their input and recommendations. Provided below are the results and recommendations.

### QUOTA APPLICANTS WITH NO ADVERSE OR DEROGATORY INFORMATION

- Mylan (9866)
- Pharmaceutics International (9874)
- St. Mary's (9896)
- Norac (9898)
- Lonza (9899)
- Purdue (9900)
- Par Pharmaceutical (9901)
- Letco Medical (9902)
- Ancor (9903)
- Pharmaceutics International (9904)
- Coating Place Inc (9905)
- Par Pharmaceuticals (9906)
- Anderson Packaging, Inc (9907)
- Watson (9908)
- Corepharma (9909)
- Aurolife (9910)
- Mikart (9912)
- Spectrum (9913)
- Johnson Matthey (9916)
- King Pharmaceuticals (9917)

(b)(4);(b)(7)(E)

Sandoz (9918)  
Metrics (9921)  
Metrics (9922)  
Pathcon (9923)

(b)(4);(b)(7)(E)

Per consultation with the field offices, DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the quota applications.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC (b)(6);(b)(7)(C)

# Memorandum



Subject

Additional Quota Letters Received as of April 5, 2010  
(DFN: 630-08.2)

Date

APR 12 2010

To

Christine A. Sannerud, Ph.D., Chief  
Drug & Chemical Evaluation Section  
Office of Diversion Control

From

*Barbara J. Bookholdt*  
Barbara J. Bookholdt, Chief  
Regulatory Section  
Office of Diversion Control

On April 5, 2010, this section received your e-mail requesting a review of sixteen (16) quota applications from fifteen (15) registered manufacturers to determine if there are any pending administrative/legal actions against these applicants and to advise ODE of the findings.

ODGR conducted reviews (NADDIS, CSA, etc), as well as surveyed the responsible field offices for their input and recommendations. Provided below are the results and recommendations.

## QUOTA APPLICANTS WITH NO ADVERSE OR DEROGATORY INFORMATION

Johnson Matthey (9928)  
Amneal (9929)  
Barr (9930)  
Noramco (9931)  
Pharmedium (9932)(2 of 2)  
Siegfried (9933)  
Watson (9837)(1 of 2)  
Watson (9837)(2 of 2)  
Lannett (9938)(1 of 2)  
Lannett (9938)(2 of 2)  
Cambrex (9939)  
Consolidated (9941)  
Safecor Health, LLC (9943)  
(Regional Service Center)  
Patheon (9944)  
Cambrex (9945)

(b)(4);(b)(7)(E)



**QUOTA APPLICANT WITH ADVERSE OR DEROGATORY INFORMATION**

(b)(4);(b)(7)(E)

(b)(4);(b)(5);(b)(6);(b)(7)(C)

Currently under review/investigation

Per consultation with the field offices, DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the quota applications.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC (b)(6);(b)(7)(C)

# Memorandum



Subject

Additional Quota Letters Received as of April 19, 2010  
(DPN: 630-08.2)


Date

MAY 10 2010

To

Christine A. Sannerud, Ph.D., Chief  
Drug & Chemical Evaluation Section  
Office of Diversion Control

From

  
Barbara J. Boockholdt, Chief  
Regulatory Section  
Office of Diversion Control

On April 19, 2010, this section received your e-mail requesting a review of fifty-two (52) quota applications from thirty (30) registered manufacturers to determine if there are any pending administrative/legal actions against these applicants and to advise ODE of the findings.

ODGR conducted reviews (NADDIS, CSA, etc), as well as surveyed the responsible field offices for their input and recommendations. Provided below are the results and recommendations.

## QUOTA APPLICANTS WITH NO ADVERSE OR DEROGATORY INFORMATION

AMRI (9950)  
AMRI (9951)  
AMRI (9952)  
AMRI (9953)  
AMRI (9954)  
AMRI (9955)  
Vintage (9957)  
Janssen Cilag (9958)  
Cody (9959)  
Cody (9960)  
Nexgen Pharma, Inc. (9962)  
Sharp Corporation (9963)  
Siegfried (9964)  
Siegfried (9965)  
Siegfried (9966)  
Siegfried (9967)  
Siegfried (9968)  
Siegfried (9969)  
CIMA (9970)  
Sandoz (9972)

(b)(4);(b)(7)(E)

Mylan (9973)  
 Actavis Mid-Atlantic (9977)  
 Arista (9978)  
 Formurex (9979)  
 Noramco Delaware (9981)  
 Noramco Delaware (9982)  
 King (9983)  
 Watson Corona (9986)  
 Watson Corona (9987)  
 Watson Corona (9988)  
 Watson Corona (9989)  
 Watson Corona (9990)  
 Amneal (9991)  
 TEVA (9992)  
 Cody (9993)  
 Hospira, Inc. KS (9994)  
 Mallinckrodt Webster Groves (9995)  
 Noramco Delaware (9997)  
 Cody (10000)  
 Akorn S. Wyckies (10001)  
 Aurolife Pharma LLC (10002)  
 B&B (10003)  
 Mylan (10004)  
 Medisca (10005)  
 HiTech (10007)  
 Noramco Georgia (10008)  
 Fisher (10010)  
 Mylan (10013)  
 Aurolife (10014)  
 Tedor Pharma Inc. (10015)  
 Hisamitsu (10016)  
 Hisamitsu (10017)

(b)(4);(b)(7)(E)

Per consultation with the field office, DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the quota applications.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC

(b)(6);(b)(7)(C)

# Memorandum



Subject

Additional Quota Letters Received as of April 29, 2010  
(DFN: 630-08.2)


Date

MAY 10 2010

To

Christine A. Sannerud, Ph.D., Chief  
Drug & Chemical Evaluation Section  
Office of Diversion Control

From

  
Barbara J. Boockholdt, Chief  
Regulatory Section  
Office of Diversion Control

On April 29, 2010, this section received your e-mail requesting a review of forty (40) quota applications from thirty-two (32) registered manufacturers to determine if there are any pending administrative/legal actions against these applicants and to advise ODE of the findings.

ODGR conducted reviews (NADIDS, CSA, etc). as well as surveyed the responsible field offices for their input and recommendations. Provided below are the results and recommendations.

## QUOTA APPLICANTS WITH NO ADVERSE OR DEROGATORY INFORMATION

AAIPharma (10040)  
Akorn (10023)  
Baxter (10035)  
Bilcare (10025)  
Boehringer Ingelheim (10054)  
Central Admixture Pharmacy Services (10051)  
Chattem (10018)  
DSM (10052)  
Epic Pharma (10037)  
Eurand (10034)  
Fisher (10042)  
Fisher (10046)  
Fisher (10047)  
Halo (10026)  
Halo (10043)  
Impax (10029) (1 of 2)  
Impax (10029) (2 of 2)  
Janssen Ortho (10031)  
Mallinckrodt (10058)  
Mallinckrodt (NA004)

(b)(4);(b)(7)(E)

- Micron Technologies Inc. (10049) (2 of 2)
- Noramco (10032)
- Noramco (10033)
- Noramco (10049) (1 of 2)
- Norwich (10024)
- Par (10030)
- Penick (10022)
- Pharmaceutics International (10027)
- Pharmaform (10028)
- Purdue (10044)
- Sharp (10039)
- Sharp Corporation (10045)
- TEVA (10019)
- TEVA (10020)
- TEVA (10021)
- Varian (10048)
- VistaPharm (10038)
- Watson (10041) (1 of 2)
- Watson (10041) (2 of 2)
- Watson (10050)

(b)(4);(b)(7)(E)

Per consultation with the field office, DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the quota applications.


If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC (b)(6);(b)(7)(C)

# Memorandum



Subject Additional Quota Letters Received as of 05-06-10 (DEN: 630-08.2)	Date  MAY 10 2010
--	-------------------------

To  
Christine A. Sannerud, Ph.D., Chief  
Drug & Chemical Evaluation Section  
Office of Diversion Control

From  
  
Barbara J. Boockholdt, Chief  
Regulatory Section  
Office of Diversion Control

On May 6, 2010, this section received your e-mail requesting a review of thirty-two (32) quota applications from twenty (20) registered manufacturers to determine if there are any pending administrative/legal actions against these applicants and to advise ODE of the findings.

ODGR conducted reviews (NAADDIS, CSA, etc), as well as surveyed the responsible field offices for their input and recommendations. Provided below are the results and recommendations.

## QUOTA APPLICANTS WITH NO ADVERSE OR DEROGATORY INFORMATION

Actavis (10075)  
AMRI (10092)  
Aurolife (10065)  
Baxter (10036)  
Consolidated Technologies (10093)  
Halo (10064)  
Johnson Matthey (10066)  
Johnson Matthey (10078)  
Johnson Matthey (10079)  
Johnson Matthey (10080)  
Johnson Matthey (10081)  
Johnson Matthey (10082)  
Johnson Matthey (10083)  
Johnson Matthey (10084)  
Johnson Matthey (10085)  
Johnson Matthey (10086)  
Johnson Matthey (10087)  
King (10076)  
Lonza (10063)  
Metrics (10088)

(b)(4);(b)(7)(E)

Norameco (10089)  
Novartis (10090)  
Novartis Consumer Health Lincoln (10097)  
Palmetto State (10062)  
Sun Pharmaceuticals (10094)  
Tris Pharma, Inc. (10095)  
Tris Pharma, Inc. (10096)  
U.S. Pharmacopeia (10091)  
Vintage (10067)  
Vintage (10068)  
Watson (10074 (1 of 2)  
Watson (10074) (2 of 2)

(b)(4);(b)(7)(E)

Per consultation with the field office, DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the quota applications.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC (b)(6);(b)(7)(C)

# Memorandum



Subject

Additional Quota Letters Received as of 05-10-10  
(DFN: 630-08.2)


Date

MAY 11 2010

To

Christine A. Sannerud, Ph.D., Chief  
Drug & Chemical Evaluation Section  
Office of Diversion Control

From

  
Barbara J. Boockholdt, Chief  
Regulatory Section  
Office of Diversion Control

On May 10, 2010, this section received your e-mail requesting a review of six (06) quota applications to determine if there are any pending administrative/legal actions against these applicants and to advise ODE of the findings.


ODGR conducted reviews (NADDIS, CSA, etc), as well as surveyed the responsible field offices for their input and recommendations. Provided below are the results and recommendations.


## QUOTA APPLICANTS WITH NO ADVERSE OR DEROGATORY INFORMATION

Ameridose, LLC (10099)  
Tris Pharma, Inc (10100)  
Cephalon, Inc (10101)  
CIMA (10102)  
CIMA (10103)  
Corepharma (10104)

(b)(4);(b)(7)(E)

Per consultation with the field offices, DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the quota applications.

If you have any questions pertaining to this information, please feel free to contact me  or SC





# Memorandum



Subject

Additional Quota Requests as of 5-20-2010  
(DFN: 630-08.2)


Date

MAY 24 2010

To

Christine A. Sannerud, Ph.D., Chief  
Drug & Chemical Evaluation Section  
Office of Diversion Control

From

  
Barbara J. Boockholdt, Chief  
Regulatory Section  
Office of Diversion Control

On May 20, 2010, this section received your e-mail requesting a review of twenty (20) quota applications from eighteen (18) registered manufacturers to determine if there are any pending administrative/legal actions against these applicants and to advise ODE of the findings.

ODGR conducted reviews (NADDIS, CSA, etc), as well as surveyed the responsible field offices for their input and recommendations. Provided below are the results and recommendations.

## QUOTA APPLICANTS WITH NO ADVERSE OR DEROGATORY INFORMATION

Hospira, Inc NC (10138)  
Physicians Total Care (10139)  
Endo New York (10140)  
Patheon (10141)  
Pharmaceutics International (10142)  
Anderson Packaging, Inc. (10143)  
Novartis Consumer Health (10145)  
AAI Pharmaceuticals (10146)  
Mallinckrodt St. Louis (10147)  
Nektar (10148)  
Nektar (10149)  
Watson (Andrx) (10152) (1 of 2)  
Watson (Andrx) (10152) (2 of 2)  
Watson (Andrx) (10153)  
Alza Vacaville (10154)  
Palmetto State (10155)  
Barr New York (10158)  
Vintage Generics Bideo (10159)  
Vintage Pharmaceutical (10160)  
DSM (10161)

(b)(4);(b)(7)(E)

Per consultation with the field offices. DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the quota applications.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC (b)(6);(b)(7)(C)

# Memorandum



Subject

Additional Quota Letters Received as of May 27, 2010  
(DFN: 630-08.2)


Date

JUN 07 2010

To

Christine A. Sannerud, Ph.D., Chief  
Drug & Chemical Evaluation Section  
Office of Diversion Control

From

  
Barbara J. Boockholdt, Chief  
Regulatory Section  
Office of Diversion Control

On May 27, 2010, this section received your e-mail requesting a review of thirty-one (31) quota applications from twenty-nine (29) registered manufacturers to determine if there are any pending administrative/legal actions against these applicants and to advise ODE of the findings.

ODGR conducted reviews (NADDIS, CSA, etc), as well as surveyed the responsible field offices for their input and recommendations. Provided below are the results and recommendations.

## QUOTA APPLICANTS WITH NO ADVERSE OR DEROGATORY INFORMATION

Tris Pharma, Inc. (10105)  
Tris Pharma, Inc. (10106)  
Medisca (10107)  
Siegfried (10108)  
Bilcare (10109)  
Siegfried (10110)  
Fisher (10111)  
Novartis (10116)  
Purdue (10117)  
ANIP (10118)  
Lehigh Valley Technologies, Inc. (10119)  
Glatt Air (10121)  
Cambrex (10122)  
Aurolife (10123)  
DSM (10124)  
UPM (10125)  
Coating Place Inc (10126)  
Abbott Laboratories North Chicago (10127)  
Watson (10128)  
Watson (10129)

(b)(4);(b)(7)(E)

Noramco Delaware (10130)  
Impax(10131)  
Pharmedium (10132)  
Cerilliant (10135)  
Dispensing Solutions, Inc (10165)  
Mallinckrodt Hobart (10169)  
Fisher (10170)  
Elite (10171)  
Catalent (10172)  
Patheon (10174)  
AAIPharma Services (10175)

(b)(4);(b)(7)(E)

Per consultation with the field office, DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the quota applications.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC

(b)(6);(b)(7)(C)


(b)(6);(b)(7)(C)

# Memorandum



Subject Additional Quota Letters Received as of June 7, 2010 (DFN: 630-08.2)	Date  JUN 10 2010
--	-------------------------

To  
Christine A. Sannerud, Ph.D., Chief  
Drug & Chemical Evaluation Section  
Office of Diversion Control

From   
Barbara J. Boockholdt, Chief  
Regulatory Section  
Office of Diversion Control

On June 7, 2010, this section received your e-mail requesting a review of twenty-four (24) quota applications from twenty (20) registered manufacturers to determine if there are any pending administrative/legal actions against these applicants and to advise ODE of the findings.

ODGR conducted reviews (NAADDIS, CSA, etc), as well as surveyed the responsible field offices for their input and recommendations. Provided below are the results and recommendations.

### QUOTA APPLICANTS WITH NO ADVERSE OR DEROGATORY INFORMATION

- Sandoz (10176)
- Aptuit (10177)
- Pharmaceutics International (10178)
- Mylan (10180)
- Aurolife (10181)
- B & B (10182)
- B & B (10183)
- TG United Liquid (10184)
- Ohm Laboratories (10185)
- Mallinckrodt St. Louis (10186)
- Chemtos (10187)
- Mylan (10188)
- Mallinckrodt St. Lois (10189)
- Collegium (10191)
- ElSohly Laboratories (10192)
- Alza (10193)
- Barr (10194)
- Acura (10199)
- Mallinckrodt St. Louis (10201)
- Sandoz (10205)

(b)(4);(b)(7)(E)

AustarPharma (10206)  
Chattem (10207)  
Metrics (10208)  
Mylan (10209)

(b)(4);(b)(7)(E)

Per consultation with the field offices. DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the quota applications.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC

(b)(6);(b)(7)(C)

(b)(6);(b)(7)(C)

# Memorandum



Subject Additional Quota Requests as of June 11, 2010 (DFN: 630-08.2)	Date  JUN 15 2010
---	-------------------------

To  
Christine A. Sannerud, Ph.D., Chief  
Drug & Chemical Evaluation Section  
Office of Diversion Control

From *Barbara J. Boockholdt*  
Barbara J. Boockholdt, Chief  
Regulatory Section  
Office of Diversion Control

On June 11, 2010, this section received your e-mail requesting a review of twenty (20) quota applications from nineteen (19) registered manufacturers to determine if there are any pending administrative/legal actions against these applicants and to advise ODE of the findings.

ODGR conducted reviews (NADDIS, CSA, etc), as well as surveyed the responsible field offices for their input and recommendations. Provided below are the results and recommendations.

## QUOTA APPLICANTS WITH NO ADVERSE OR DEROGATORY INFORMATION

- Nexgen Pharma, Inc. (10212)
- Mallinckrodt St. Louis (10213)
- Patheon (10214)
- Mikart (10215)
- Emerson Resources, Inc. (10216)
- Catalent (10217)
- B & B (10218)
- Impax (10219) (1 of 2)
- Impax (10219) (2 of 2)
- Hospira, Inc. NC (10220)
- Watson (10221)
- Watson (10222)
- DSM (10226)
- Johnson Matthey (10227)
- Catlent (10228)
- Noramco (10229)
- Cambrex (10230)
- Jerome Stevens (10231)
- Noramco (10232)
- Dispensing Solutions, Inc. (10233)

(b)(4);(b)(7)(E)

Per consultation with the field offices, DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the quota applications.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC

(b)(6);(b)(7)(C)



# Memorandum



Subject

Additional Quota Letters Received as of June 24, 2010  
(DFN: 630-08.2)

Date

**JUL 01 2010**

To

Christine A. Sannerud, Ph.D., Chief  
Drug & Chemical Evaluation Section  
Office of Diversion Control

From

*Barbara J. Brockholdt*  
Barbara J. Brockholdt, Chief  
Regulatory Section  
Office of Diversion Control

On June 24, 2010, this section received your e-mail requesting a review of thirty-two (32) quota applications from twenty-eight (28) registered manufacturers to determine if there are any pending administrative/legal actions against these applicants and to advise ODE of the findings.

ODGR conducted reviews (NADDIS, CSA, etc), as well as surveyed the responsible field offices for their input and recommendations. Provided below are the results and recommendations.

## **QUOTA APPLICANTS WITH NO ADVERSE OR DEROGATORY INFORMATION**

Fisher Virginia (10238)  
Sigma (10239)  
CorePharma Wood Ave (10241)  
Sandoz (formerly Geneva Pharmaceuticals, Inc) (10242)  
Vintage Generics Bideo (10243)  
Mylan Chestnut Ridge Road West Virginia (10244)  
Mylan Chestnut Ridge Road West Virginia (10245)  
Watson Utah (10247)  
Axcentria (10249)  
Rhodes (10250)  
Neos Therapeutics, LP (formerly Pharmafab) (10251)  
PalliRx, Inc. (10253)  
Epic (10254)  
Boehringer Ingelheim (10255)  
Fisher Virginia (10256)  
Johnson Matthey (10262)  
Cerilliant (10263)  
Rhodes (10264)  
Sigma (10266)  
Cody (10267)

(b)(4);(b)(7)(E)

Par (10268) (1 of 2)  
Par (10268) (2 of 2)  
Ortho McNeil Pharmaceutical (10269)  
Alza Vacaville (10270)  
Vintage Generics Bidco (10271)  
Janssen Puerto Rico (10274)  
Novartis Consumer Health Lincoln (10275)  
Impax Pennsylvania (10276)  
Collegium Pharmaceutical (10277)  
KVK Tech. Inc. (10278)  
Bileare (10279)  
Sure-Tech (10280)

(b)(4);(b)(7)(E)

Per consultation with the field office, DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the quota applications.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC (b)(6);(b)(7)(C)

# Memorandum



Subject Additional Quota Requests as of July 1, 2010 (DFN: 630-08.2)	Date <b>JUL 06 2010</b>
--	----------------------------

To  
Christine A. Sannerud, Ph.D., Chief  
Drug & Chemical Evaluation Section  
Office of Diversion Control

From  
*Barbara J. Bockholdt*  
Barbara J. Bockholdt, Chief  
Regulatory Section  
Office of Diversion Control

On July 1, 2010, this section received your e-mail requesting a review of nineteen (19) quota applications from fifteen (15) registered manufacturers to determine if there are any pending administrative/legal actions against these applicants and to advise ODI of the findings.

ODGR conducted reviews (NADDIS, CSA, etc), as well as surveyed the responsible field offices for their input and recommendations. Provided below are the results and recommendations.

## QUOTA APPLICANTS WITH NO ADVERSE OR DEROGATORY INFORMATION

- Hospira, Inc. NC (10236)
- Hospira, Inc. NC (10252)
- BD Medical (10282)
- Barr Laboratories (10283)
- Hisamitsu California Laboratories (10284)
- Coating Place Inc (10285)
- Chattem (10286)
- Sigma-Aldrich Research Biochemicals (10288)
- AAI Pharma (10291)
- Wildlife Pharmaceuticals (10295)
- Chattem (10296)
- Chattem (10297)
- Chattem (10298)
- Par Pharmaceuticals (10299) (1 of 2)
- Par Pharmaceuticals (10299) (2 of 2)
- Epic Pharma (10300)
- Cerilliant (10303)
- BI Roxanne (10304)
- Sharp Corporation (10305)

(b)(4);(b)(7)(E)

Per consultation with the field offices, DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the quota applications.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC (b)(6);(b)(7)(C)

# Memorandum



Subject

Additional Quota Letters Received by July 12, 2010  
(DFN: 630-08.2)


Date

JUL 14 2010

To

Christine A. Sannerud, Ph.D., Chief  
Drug & Chemical Evaluation Section  
Office of Diversion Control

From

  
Barbara J. Boockholdt, Chief  
Regulatory Section  
Office of Diversion Control

On July 12, 2010, this section received your e-mail requesting a review of twenty-five (25) quota applications from twenty-four (24) registered manufacturers to determine if there are any pending administrative/legal actions against these applicants and to advise ODE of the findings.

ODGR conducted reviews (NADDIS, CSA, etc), as well as surveyed the responsible field offices for their input and recommendations. Provided below are the results and recommendations.

## QUOTA APPLICANTS WITH NO ADVERSE OR DEROGATORY INFORMATION

Novartis Consumer Health Lincoln (10306)  
VistaPharm (10307)  
Siemens Healthcare Diagnostics Inc. (10308)  
Eon/Sandoz (10309)  
King (10310)  
Mallinckrodt (10311)  
Catalent (10312)  
Siegfried (10313)  
Amerisource (10317)  
Hospira, Inc. NC (10318)  
Ameridose, LLC (10319)  
Ameridose, LLC (10320)  
Noramco Delaware (10321)  
Paddock (10323)  
Cambrex (10324)  
Medisca (10326)  
CorePharma (10327)  
Actavis (10328)  
Cody (10330)  
Biosite (10331)

(b)(4);(b)(7)(E)

Norac (10333)  
Watson (10334)  
3M (10336)  
Fisher (10337)  
Sun Pharmaceuticals (10338)

(b)(4);(b)(7)(E)

Per consultation with the field offices, DEA does not have sufficient grounds to limit, restrict, or deny quota requests from these registrants. Based on this information, ODG suggests that you proceed with the completion of the quota applications.

If you have any questions pertaining to this information, please feel free to contact me (b)(6);(b)(7)(C) or SC

(b)(6);(b)(7)(C)